StockData
Cytek Biosciences, Inc. logo

Cytek Biosciences, Inc. (CTKB) stock

CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/300% below fair value
$6.12−0.20 (-3.16%)

Close on Nov 20, 2026Market cap $795.50MP/E –Yield –

Cytek Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Cytek Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$12.08M, down 211.1% year over year. For fiscal 2025 it was -$8.77M, down 140.1% from the year before. The highest annual figure on record is $21.85M in fiscal 2024.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$8.77M-140.1%
FY2024Dec 31, 2024$21.85M+3352.4%
FY2023Dec 31, 2023$633.00K–
FY2022Dec 31, 2022-$21.98M-8362.8%
FY2021Dec 31, 2021$266.00K-98.0%
FY2020Dec 31, 2020$13.61M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$849.00K–
Q1 FY2026Mar 31, 2026-$4.90M–
Q4 FY2025Dec 31, 2025-$1.77M-260.7%
Q3 FY2025Sep 30, 2025-$4.56M-137.3%
Q2 FY2025Jun 30, 2025-$1.47M-128.5%
Q1 FY2025Mar 31, 2025-$974.00K-128.7%
Q4 FY2024Dec 31, 2024$1.10M-86.2%
Q3 FY2024Sep 30, 2024$12.21M–
Q2 FY2024Jun 30, 2024$5.15M–
Q1 FY2024Mar 31, 2024$3.39M+44.1%
Q4 FY2023Dec 31, 2023$8.01M–
Q3 FY2023Sep 30, 2023-$5.57M–
Q2 FY2023Jun 30, 2023-$4.16M–
Q1 FY2023Mar 31, 2023$2.35M–
Q4 FY2022Dec 31, 2022-$337.00K-108.1%
Q3 FY2022Sep 30, 2022-$8.61M–
Q2 FY2022Jun 30, 2022-$10.77M–
Q1 FY2022Mar 31, 2022-$2.26M-258.5%
Q4 FY2021Dec 31, 2021$4.15M-63.7%
Q3 FY2021Sep 30, 2021-$147.00K-108.6%
Q2 FY2021Jun 30, 2021-$5.17M–
Q1 FY2021Mar 31, 2021$1.43M–
Q4 FY2020Dec 31, 2020$11.44M–
Q3 FY2020Sep 30, 2020$1.72M–

More Cytek Biosciences figures

See a number that looks wrong?